Trial Profile

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 29 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Precemtabart tocentecan (Primary) ; Tipiracil/trifluridine
Indications Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms PROCEADE-CRC-03
Sponsors EMD Serono Research & Development Institute

21 May 2026 According to a Merck & Co media release, first patient has been dosed.
08 May 2026 Planned End Date changed from 31 Oct 2029 to 16 Oct 2029.
08 May 2026 Planned primary completion date changed from 25 Dec 2028 to 16 Oct 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com